title: Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats.
abstract: Doxorubicin (DOX), a widely used anticancer drug, has a dose-dependent cardiotoxicity, attributed mainly to free radical formation. The cardiomyocyte oxidative stress occurs rapidly after DOX treatment, resulting in harmful modifications to proteins, lipids, and DNA. Previous data showed that oral l-glutamine (Gln) prevented cardiac lipid peroxidation and maintained normal cardiac glutathione (GSH) levels in DOX-treated rats. Our aim in this study was to examine the effect of Gln on DOX-induced cardiac oxidative stress in a tumor-bearing host. Female Fisher344 rats with implanted MatBIII mammary tumors were randomized into 2 groups: a Gln group that received l-Gln (1 g.kg(-1).d(-1)) (n = 10) via a Gln-enriched diet and/or gavage with 50% Gln suspension during the whole experiment and a control group that was fed the same diet formulation without Gln and/or were gavaged with water. All rats received a single injection of 12 mg/kg DOX and were killed 3 d later. GSH levels of hearts, livers, tumors, and blood, as well as cardiac histological alterations, lipid peroxidation, peroxinitrite levels, and caspase-3 activation were determined. Cardiac physiologic alterations were assessed by ultrasound imaging before and 3 d after DOX administration. The Gln supplementation resulted in lower cardiac lipid peroxidation and peroxintrite levels and elevated cardiac catalase enzyme activity and GSH compared with the controls, without affecting those of the tumors. DOX-induced alterations of the echocardiographic parameters were significantly reduced in the Gln-supplemented rats. These data indicate that Gln is able to reduce the oxidative damage of cardiomyocytes that occurs soon after DOX administration and thus protects the heart of a tumor-bearing host from DOX-induced cardiomyopathy.
authors.affiliation: Departments of Surgery/Breast Surgical Oncology, Little Rock, AK 72205, USA. todorovavalentinak@uams.edu
authors.forename: Valentina K
authors.initials: VK
authors.lastname: Todorova
authors.forename: Yihong
authors.initials: Y
authors.lastname: Kaufmann
authors.forename: Leah
authors.initials: L
authors.lastname: Hennings
authors.forename: V Suzanne
authors.initials: VS
authors.lastname: Klimberg
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D004435:Eating / Q000187:drug effects; D005260:Female; D005973:Glutamine / Q000008:administration & dosage* / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D006331:Heart Diseases / Q000139:chemically induced* / Q000517:prevention & control; D015227:Lipid Peroxidation / Q000187:drug effects; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D030421:Peroxynitrous Acid / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D000970:Antineoplastic Agents; D005973:Glutamine; D030421:Peroxynitrous Acid; D004317:Doxorubicin; D005978:Glutathione